Cambridge Healthtech Institute’s 7th Annual
CAR Ts, TCRs and TILs
Engineering Clinically Relevant Adoptive T Cell Therapies
May 6-7, 2020
Cambridge Healthtech Institute’s 7th Annual CAR Ts, TCRs and TILs focuses on the latest tools, techniques, and engineering strategies driving the development of cellular immunotherapies for cancer and immune disorders. Focus will be given to clinical progress with Chimeric Antigen Receptors (CAR), T Cell Receptors (TCR), Tumor Infiltrating Lymphocytes (TIL) and Natural Killer (NK) cells, with dedicated sessions on off-the-shelf platforms, solid tumors and lessons learnt from the clinic.
Preliminary Agenda
TRANSLATIONAL SUCCESS IN CAR T
Development, Clinical Results and Translational Analysis of a T Cell Product for Mantle Cell Lymphoma
Adrian Bot, PhD, Vice President, Translational Sciences, Kite Pharma, a Gilead Company
Progress in Solid Tumors: CAR T Therapy in Mesothelioma – An Update
Prasad S. Adusumilli, MD, FACS FCCP, Deputy Chief and Associate Attending, Thoracic Surgery; Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center (CTC), Memorial Sloan-Kettering Cancer Center; Associate Professor, Cardiothoracic Surgery, Weill Cornell Medicine
ALLOGENIC, OFF-THE-SHELF THERAPIES
Latest Developments in Allogenic T Cell Therapy
Tom Van Blarcom, PhD, Head, Protein Engineering, Allogene Therapeutics
Gene Edited Off-the-Shelf Immunotherapies
Laurent Poirot, PhD, Vice President, Immunology, Cellectis
Non-Gene-Edited Allogeneic CAR T Cells: Maximizing Safety and Persistence
Peggy Sotiropoulou, PhD, Director, Research & Development, Celyad
Translation of Pluripotent Cell-Derived T and NK Cells as a Cornerstone Approach for Off-the-Shelf Cancer Immunotherapy
Bob Valamehr, PhD, Chief Development Officer, Fate Therapeutics
TCRs
New Broadly Expressed Cancer Targets from Successful TIL Therapy
Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine
A Novel TCR Engineering Approach to Eliminate Tumor Cells
Rajkumar Ganesan, PhD, Director, Antibody Engineering, Bispecifics and CAR T
Clinical Experience with T Cells Expressing NY-ESO-1 TCR and CRISPR Edited to Eliminate Endogenous TCR and PD-1
Simon F. Lacey, PhD, Director, Translational and Correlative Studies Laboratory, Center for Cellular Immunotherapies, University of Pennsylvania
TILs
Tumor-Infiltrating Lymphocytes Therapy for Solid Tumors
Chantale Bernatchez, PhD, Assistant Professor, Department of Melanoma Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Advancements in Tumor-Infiltrating Lymphocytes in Treatment of Solid Tumors
Corrine Epperly, Senior Vice President, Strategy and Operations, Iovance Biotherapeutics
* The program is subject to change without notice, due to unforeseen reason.
Sponsor updated
2020 PROGRAMS
View By:









Emerging Indications for Therapeutic Antibodies
Immunogenicity Case Studies and Clinical Management
Improving Immunotherapy Efficacy and Safety
Engineering Antibody-Drug Conjugates
Gene Therapy: Advancing from Bench to Clinic
Immunogenicity Assessment and Regulatory Approval of Biologics
Advancing Bispecific Antibodies and Combination Therapy to the Clinic
Optimizing Bioassays for Biologics
Clinical Progress of Antibody-Drug Conjugates
Characterization for Novel Biotherapeutics
Cell and Gene Therapy Analytics
Engineering Bispecific Antibodies
Protein Expression System Engineering